Ahead of the 2019 eyeforpharma Barcelona conference, we asked speaker Pol Vandenbroucke – chief medical officer of the Hospital Business Unit at Pfizer – for his view
MSD and Pfizer were 2018’s top gainers on the Dow Jones Industrial Average for the calendar year, with both companies bucking the trend of an otherwise lacklustre year for the index.
GlaxoSmithKline has announced its second major deal this month, signing an agreement with Pfizer to combine its consumer health business and form a joint venture with combined annual sales
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
